Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials
Farah Yasmin, Hala Najeeb, Abdul Moeed, Wardah Hassan, Mahima Khatri, Muhammad Sohaib Asghar, Ahmed Kunwer Naveed, Waqas Ullah, Salim Surani
PLOS ONE, doi:10.1371/journal.pone.0266245
Background Colchicine has been used an effective anti-inflammatory drug to treat gout diseases. Owing to its pharmacodynamic of inhibiting interleukins, it has been repurposed to target the cytokine storm post-SARS-CoV-2 invasion. The goal of this meta-analysis was to evaluate the safety profile of colchicine in COVID-19 patients using the gold-standard randomised-control trials.
Methods Electronic databases (Pubmed, Google Scholar, and Cochrane) were systematically searched until June 2021 and RCTs were extracted. Outcomes of interest included allcause mortality, COVID-19 severity, mechanical ventilation, C-reactive protein and D-dimer levels. Using a random-effects model, dichotomous outcomes were pooled using odds ratios (OR) through the generic inverse variance formula while weighted mean differences were calculated using the Wan's method. P-values < 0.05 were considered statistically significant for all outcomes.
Results A total population of 16,048 from five RCTs were included in the analysis. Of this, 7957 were randomized to colchicine, and 8091 received standard care, with an average age of 60.67 years. Colchicine was observed to significantly reduce COVID-19 severity (OR: 0.41, 95% CI [0.22, 0.76]; p = 0.005), and CRP levels (WMD: -19.99, 95% CI [-32.09, -7.89]; p = 0.001). However, there was no significant difference in D-dimer levels (WMD: 0.31, 95% CI [-0.61, 1.23]; p = 0.51), mechanical ventilation (OR: 0.42, 95% CI [0.17, 1.03]; p = 0.06; I 2 = 74%) and all-cause mortality (OR: 0.98, 95% CI [0.83, 1.16]; p = 0.84) among patients receiving colchicine or standard care.
References
Ali, Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19, Journal of Medical Virology,
doi:10.1002/jmv.26097Bikdeli, Madhavan, Jimenez, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J Am Coll Cardiol. Published,
doi:10.1016/j.jacc.2020.04.031Brunetti, Diawara, Tsai, Firestein, Nahass et al., Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19, Journal of clinical medicine,
doi:10.3390/jcm9092961Cronstein, Molad, Reibman, Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils, J Clin Invest,
doi:10.1172/JCI118147Deftereos, Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2020.13136Della-Torre, Campochiaro, Cavalli, Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-218122Ferro, Elefante, Baldini, COVID-19: the new challenge for rheumatologists, Clin Exp Rheumatol
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin Exp Pharmacol Physiol,
doi:10.1111/1440-1681.13488Landray, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, medRxiv,
doi:10.1101/2021.05.18.21257267Le, FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome, Oncologist,
doi:10.1634/theoncologist.2018-0028Li, Liu, Mao, Predictive values of neutrophil to lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis, Crit Care,
doi:10.1186/s13054-020-03374-8Liberati, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ,
doi:10.1136/bmj.b2700Lopes, Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open,
doi:10.1136/rmdopen-2020-001455Mareev, Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiya,
doi:10.18087/cardio.2021.2.n1560Martinon, Pe ´trilli, Mayor, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature,
doi:10.1038/nature04516Notley, Tinlin, Sawyer, Begbie, Lillicrap, The factor VIII acute phase response requires the participation of NFκB and C/EBP, Thrombosis and Haemostasis
Parra-Medina, Sarmiento-Monroy, Rojas-Villarraga, Garavito, Montealegre-Gomez et al., Colchicine as a possible therapeutic option in COVID-19 infection, Clin. Rheumatol,
doi:10.1007/s10067-020-05247-5Qin, Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin. Infect. Dis,
doi:10.1093/cid/ciaa248Reyes, Hu, Teperman, Muskardin, Tardif et al., Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Annals of the rheumatic diseases,
doi:10.1136/annrheumdis-2020-219174Scarsi, Piantoni, Colombo, Airo, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Annals of the Rheumatic Diseases,
doi:10.1136/annrheumdis-2020-217712Sproston, Ashworth, Role of C-reactive protein at sites of inflammation and infection, Frontiers in Immunology,
doi:10.3389/fimmu.2018.00754Sterne, RoB 2: A revised tool for assessing risk of bias in randomised trials, BMJ,
doi:10.1136/bmj.l4898Tardif, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir. Med,
doi:10.1016/S2213-2600%2821%2900222-8Tayer-Shifman, Ben-Chetrit, Familial Mediterranean fever and hypercoagulability, Mediterranean journal of hematology and infectious diseases,
doi:10.4084/MJHID.2011.017Turk, Turk, Malkan, Haznedaroglu, Three critical clinicobiological phases of the human SARS-associated coronavirus infections, Eur. Rev. Med. Pharmacol. Sci,
doi:10.26355/eurrev%5F202008%5F22660Wan, Wang, Liu, Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med. Res. Methodol,
doi:10.1186/1471-2288-14-135Wang, Wu, Zhang, C-reactive protein level may predict the risk of COVID-19 aggravation, Open Forum Infect Dis,
doi:10.1093/ofid/ofaa153Yao, D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study, J. Intensive Care,
doi:10.1186/s40560-020-00466-zZhang, Li, Shen, Chen, Qi, Rational use of tocilizumab in the treatment of novel coronavirus pneumonia, Clin Drug Investig,
doi:10.1007/s40261-020-00917-3Zhang, Wu, Li, Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105954Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736%2820%2930566-3
